Lanean...
Pretargeted Radioimmunotherapy for Hematologic and Other Malignancies
Radioimmunotherapy (RIT) has emerged as one of the most promising treatment options, particularly for hematologic malignancies. However, this approach has generally been limited by a suboptimal therapeutic index (target-to-nontarget ratio) and an inability to deliver sufficient radiation doses to tu...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Mary Ann Liebert, Inc.
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2936263/ https://ncbi.nlm.nih.gov/pubmed/20423225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2010.0759 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|